

Eiken Chemical Co., Ltd.

illumina, Inc.

Eiken Chemical and Illumina Announce Agreement to Develop and Commercialize a Molecular Diagnostic System in Japan

Using next-generation sequencing the partnership will contribute to the progress of personalized medicine

TOKYO, Japan —June 21, 2021— Eiken Chemical Co., Ltd. (Headquarters: Taito Ward, Tokyo) and Illumina, Inc. (Headquarters: San Diego, CA, USA), today announced an agreement for the development and commercialization of a molecular diagnostic system using next-generation sequencing (NGS).

Under the agreement, Eiken Chemical will develop a companion diagnostic system using Illumina's medical device MiSeq™Dx system and contribute to the progress of personalized medicine.

Eiken Chemical President and CEO, Morifumi Wada, said the partnership would accelerate the adoption of NGS-based in vitro diagnostic (IVD) workflow to enhance our understanding of the clinical benefits for patients and healthcare providers.

“We are very pleased with this important partnership that will combine our complementary capabilities in advancing the use of powerful technologies to improve the outcomes of patients in Japan ” said Mr. Wada.

Taking advantage of proven Illumina sequencing by synthesis (SBS) chemistry, the MiSeq™Dx Sequencing System provides Eiken Chemical with the tools to create accurate diagnostic testing. The partnership will initially focus on NGS-based IVD kits to support the management of non-small cell lung cancer (NSCLC) patients.

Illumina Vice President and General Manager of Asia Pacific and Japan, Ms. Gretchen Weightman, explained that the partnership represents an important milestones for patients and the clinical community in Japan.

“Illumina’s comprehensive technologies, coupled with Eiken Chemical’s expertise, will bring the power of NGS to clinical diagnostics and demonstrates our commitment to improving patient outcomes,” said Ms. Weightman.

Guided by its commitment to “protect the health of the public through health care services”, Eiken Chemical will continue to provide products and services that support the health and lives of people.

-Ends-

ABOUT EIKEN CHEMICAL CO., LTD.

Eiken Chemical, founded in 1939, is a general manufacturer of clinical diagnostics that provides excellent products and services in Japan and overseas. Under our management philosophy of “Protect the health of the public through health care services,” we strive to research and develop products and technologies in a wide range of clinical diagnostics that meet advanced medical needs. To learn more, visit <https://www.eiken.co.jp/en/>

ABOUT ILLUMINA

Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as the global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit www.illumina.com and connect with us on [Twitter](#), [Facebook](#), [LinkedIn](#), [Instagram](#), and [YouTube](#).

Media:

Eiken Chemical

Sustainability Department
koho@eiken.co.jp

Illumina

Dr. Karen Birmingham
EMEA: +44 7500 105665
US: 646.355.2111
kbirmingham@illumina.com